BeiGene R&D Day unveils data on multiple potential FIC/BIC candidates

BeiGene's new pipeline layout has once again demonstrated its deep R&D foundation. As zanubrutinib has grown into a global blockbuster, the next success in the hematology oncology field is brewing, with satralizumab submitted for marketing approval, and a series of promising candidates in solid tumors poised to achieve multiple proof-of-concepts this year.POC) milestone.

A deeper signal released through the pipeline layout is that BeiGene, Inc. is advancing toward becoming a global oncology pharmaceutical giant, demonstrating its commitment throughMNCIts system and strategy continue to innovate and deliver, leveraging global capabilities to elevate a global vision.

The next victory in the field of hematologic malignancies

BeiGene has identified a solid foothold in the field of hematology oncology, focusing on niche markets that are large in size and fast-growing.CLLand continues to deepen its efforts, becoming the only company in3individualCLLAll have potential in the underlying mechanism of actionBICThe company of the product.

The success of zanubrutinib speaks for itself. Despite not gaining an early foothold in the U.S. market, especially inCLLIndications were approved later than those of ibrutinib and acalabrutinib9Nian He3In annual terms, Zanubrutinib still achieved an overtaking. The core logic behind this success lies in locking onto“Big medicine”Variety and based onBICIterating molecules based on the philosophy. Zanubrutinib is just the beginning; BeiGene's hematology portfolio is about to be renewed, with the new flagship product, sutoclax, already filed for approval in China and expected to advance to global filing in the second half of this year.

As the new generationBCL-2Inhibitor, Zanubrutinib is attempting to replicate the success path of Zanubrutinib. Compared to Venetoclax, Zanubrutinib's efficacy has improved14doubled, and selectivity has improved6times, and the half-life is also significantly shortened. Optimization in molecular design will translate into improved efficacy, safety, and convenience of administration.

With two drugs approved, BeiGene's strategic brilliance comes to light, as it transcends the mindset of single-agent therapy, delivering even stronger combination regimens based on highly effective individual drugs. Current clinical data suggest that the all-oral Sotorasurviv+Zanubrutinib in first-line treatmentCLL/SLLor relapse/Refractory (R/R）CLL/SLLin various hematologic tumors, demonstrating deep and durable response, with the potential to become the optimal combination therapy. Based on these positive results, BeiGene, Inc. has initiated3BeiGene GlobalIIIPhase clinical.

If Sotorasib represents a horizontal expansion for BeiGene in the field of hematological tumors, thenBTK CDACDrugBGB-16673is a strategic move to advance its deepened布局, expected to overcome traditionalBTKdrug resistance issues with inhibitors, also implies that BeiGene, Inc. has the capability to develop more scarceFICMedication.

DevelopmentFICThe molecular pathway represents the highest-risk route in innovative drug development. However, based on existing data,BGB-16673The finished drug has already achieved a certain level of certainty.IPeriodCaDAnCe-101Research shows,BGB-16673InR/R CLL、R/R WM、R/R FL、MZLin patientsORRrespectively84.8%、84.4%、41.7%、50%, and in cases with extremely poor prognosisRichter'sResponses were observed in converted patients. That is,BGB-16673The range of indications may be quite broad.

The clinical development approach for superiority verification is alsoBGB-16673manifested in the body. Targeting previously covalent-treatedBTKinhibitor treatmentR/R CLL/SLLPatient, BeiGene, Inc. has initiatedBGB-16673Compare pirtobrutinib globallyIIIPeriodCaDAnCe 304Research.

The above three major products will establish BeiGene's foundation in the hematology领域, and more new therapies will help BeiGene expand its footprint in the future, includingTCell connector (TCE), cell therapy, and macrophage engagers. InTCEThe赛道, BeiGene, Inc. already has some differentiated early-stage assets in its pipeline.CD19/CD20/CD3San Kang,BAFFR/CD22/CD3San Kang HeCD20/CD28Both bispecific antibodies have advanced toINDStage.

The strength of solid tumors has reached a moment of reevaluation

Beyond the sustained spotlight on hematologic tumors, BeiGene, Inc. has quietly built a well-structured network in the solid tumor field, poised to launch a multi-track relay breakthrough. Behind this race lies BeiGene's strategic depth and execution capability, as its underestimated strength in solid tumors comes into focus for reevaluation.

BeiGene's story in solid tumors is led by tislelizumab. The beginning of the story was not particularly impressive.——AsPD-1A latecomer in the race, tislelizumab faces a landscape alreadyKDrug,OThe market landscape is dominated by drugs. However, BeiGene, Inc. is steadily expanding the solid tumor indications for tislelizumab. The efficiency of tislelizumab's label expansion is remarkable, since2019Since its approval for marketing at the end of last year, it has been indicated for urothelial carcinoma, non-small cell lung cancer, hepatocellular carcinoma, etc.10Major types of cancer.

More strategically significant is the validation of its global capabilities. To date, tislelizumab has been approved in Europe.7Indications, approved in the U.S.3The following indication has the second widest overseas rollout afterKYaohuoOMedicine. This is not only an expansion of the commercial footprint, but also a strong validation of BeiGene's global clinical development and registration capabilities.

InPD-1Beyond the boundaries of therapy coverage, BeiGene, Inc. is building a more diversified treatment matrix.HER2The dual-targeting antibody zanidatamab was approved for market launch in China last month, directly targetingHER2Unmet clinical needs in the population with positive solid tumors.

The real breakthrough power lies in deeper pipeline development. BeiGene, Inc. has a focused approach on lung cancer, breast cancer/A series of highly differentiated potential molecules have been developed in tumor areas with strong treatment needs, such as gynecological cancers and gastric cancer.

In breast cancer/In the field of gynecological cancers, BeiGene, Inc.'s strategy demonstrates“Precision strike”features. In response toHR+/HER2-The treatment pain points of the breast cancer population, BeiGene, Inc.CDKmulti-layered布局 on the target, with highly selective inhibitors and potent degraders developed in parallel, addressing the issue through a dual-pronged approachCDK4/6Issues of resistance and hematological safety with inhibitors.

Complete firstPOCofBGB-43395（CDK4inhibitor) has demonstrated favorable tolerability, pharmacodynamic properties, and clear clinical responses in early studies, with potentially best-in-class hematological safety characteristics. Following the data readout from the dose optimization randomized expansion phase,BGB-43395will enter in the second half of the yearIIIphase period.

BG-68501（CDK2inhibitor) also demonstrated manageable safety and preliminary anti-tumor activity in early studies, with dose escalation up to200mgDose-limiting toxicity has not yet been observed (DLT), the disease control rate was51.5%（17/33). Under the same layout logic, BeiGene, Inc. has also developed compounds with superior selectivity and greater potencyCDK2degradantBF-75098The molecule will enter clinical trials by the end of the year.

BG-C9074（B7-H4 ADC) demonstrated preliminary efficacy in the first human study, with a confirmed objective response rate (cORR) is24%, where6mg/kgof the dose groupcORRReached43%. Judging from the results of the biomarkers,BG-C9074YesB7-H4Patients with higher expression derived greater benefit. Based on this, BeiGene, Inc. will in this yearQ3Open tumor-specific expansion cohorts for breast cancer and gynecological malignancies to further confirmBG-C9074InB7-H4Efficacy and safety in patients with high expression tumors.

In the field of lung cancer, BeiGene, Inc. is building an industry-leading portfolio of products.BGB-58067（PRMT5inhibitor) andBG-89894（MAT2AInhibitor) did not occur during the monotherapy dose-escalation study phaseDLT, with a small number of patients achieving objective responses early on. Notably, BeiGene, Inc. has once again demonstrated the comprehensiveness and foresight of its pipeline strategy in the field of lung cancer.——The only one inPRMT5andMAT2AA company with clinical-stage programs targeting two high-potential lung cancer targets.

In the field of gastric cancer, BeiGene, Inc. focuses on exploring innovative biological mechanisms, particularly onRASDeep development of the channel aroundRASPathway, developed by BeiGene, Inc.KRASinhibitor,KRAS CDAC、RAS（ON) inhibitors and other drugs, among whichKRAS CDACAchieved in preclinical studiesKRASnear-complete degradation will occur in2026Entered clinical trials in the second half of the year.

The next six months will be critical for BeiGene, Inc.'s solid tumor pipeline.——8individualPOCMilestones will be achieved sequentially, includingBG-T187（EGFR/METthree anti),BG-60366（EGFR CDAC）、BG-C137（FGFR2b ADC) and other drugs. The emergence of these potential molecules has made BeiGene, Inc.'s capabilities in target discovery, mechanism exploration, and technological innovation more tangible.

Advancing toward becoming a global oncology pharmaceutical leader

Reviewing BeiGene, Inc.'s R&D pipeline, whether it's the continuous evolution in hematologic tumors or the diverse breakthroughs in solid tumors, the breadth (covering major cancer types) and depth of its portfolioFIC/BICPotential molecules are emerging, and the company has already demonstrated the development trajectory of a global oncology giant. However, the pipeline layout is merely the tip of the iceberg; the true transformation is taking place in the fundamental restructuring of the R&D system.

The construction and evolution of all systems are based on team building. BeiGene, Inc.'s R&D team is highly productive and mature in capability. Among them, the preclinical team brings together1200+Researchers, one of the world's largest teams dedicated to oncology drug discovery. With collaboration from the preclinical team, BeiGene, Inc.'s preclinical pipeline has expanded to82Meanwhile, as BeiGene, Inc. scales up, it continues to advance innovation and upgrades in its technology platforms.CDAC、ADC, dual antibody/Multiple platforms, including poly-resistant ones, are operating efficiently, continuously empowering the in-depth expansion of the pipeline.

Of course, if one solely pursues growth in the number of pipelines, it is easy to fall into homogenized competition. In fact, BeiGene, Inc. applies extremely rigorous evaluation criteria for its preclinical projects and terminates those that fail to meet its standards. In three and a half years, BeiGene has terminated60+Preclinical projects reflect its emphasis on resource allocation efficiency.

Clinical development team from2013Started construction at the beginning of the year, now scaled up to3700+Employees, meticulously covering various functions. This team has brought truly global clinical development capabilities to BeiGene, Inc., completely摆脱了CRODependency, self-driven advancement96a clinical trial involving30A clinical product. In execution, BeiGene, Inc. consistently adheres to a global enrollment strategy with multi-regional coverage, ensuring not only diversity in patient ethnicity but also access to specific hard-to-recruit populations, thereby fulfilling its commitment to patients worldwide.

POCPhase, BeiGene, Inc. emphasizes efficiency above all, such as an average duration of only for dose escalation cohorts7.1Week; average time to initiate dose expansion after determination of recommended dose4.4Zhou. In the future, it will also leverage automation andAITechnology to maximize the efficiency of clinical trials.

Leveraging its robust global R&D organizational structure, BeiGene, Inc. has created advantages in time, cost, and quality in pipeline development, significantly shortening the innovation drug development cycle and enabling the concurrent advancement of dozens of highly complex projects, ensuring more“Relay race”Can proceed smoothly.

From the comprehensive expansion in hematologic tumors to multiple breakthroughs in solid tumors, BeiGene, Inc. is demonstrating through concrete actions what it means to be a truly global innovative oncology company. In this process, it has not only achieved continuous breakthroughs at the product level, but more importantly, undergone a transformation in systemic capabilities. As a significant milestone approaches, these accumulated strengths will become BeiGene's foundation for the next phase.5year,10The key support enabling continued leaps forward and ultimately positioning the company among the world's leading pharmaceutical enterprises.